Drug-resistant TB: latest news

Drug-resistant TB resources

Drug-resistant TB features

Drug-resistant TB news from aidsmap

More news

Drug-resistant TB news selected from other sources

  • Final fight pays off, XXDR-TB & HIV patient cured

    Once an active case of extremely drug resistant (XXDR-TB) strain of tuberculosis or totally drug resistant (TDR) TB, 40-year-old Rashid Khan (name changed), has now been completely cured of his disease. Despite having total drug resistance and HIV infection, Khan got cured a few days ago. At one stage he was receiving a cocktail of 18–20 drugs between his HIV and TB regimes. But Bedaquiline made a huge difference in his treatment. He is off medicine now.

    24 March 2015 | DNAIndia
  • MSF: More than a quarter of MDR-TB cases in Swaziland not caught by “front line of defense” in fighting the disease

    The nonprofit medical humanitarian organization Médecins Sans Frontières is recommending that all patients in Swaziland who have tested positive for TB, but rapid molecular testing has found negative for drug-resistance undergo further testing, following findings that a mutation has made more than a quarter of multidrug-resistant strains undetectable by the widely used test.

    20 March 2015 | Science Speaks
  • Lancet: Phase 2b trial results of novel TB regimen show potential to shorten treatment

    A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy, worked for people with multi-drug-resistant (MDR) TB, and did so in a quarter of the time, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, STAND, designed to bring this regimen through the last stage of testing, has begun. The PaMZ regimen uses pretomanid, a new drug; moxifloxacin, an established antibiotic that is experimental as a TB treatment; and pyrazinamide, an established TB drug. Twenty percent of the TB patients enrolled in NC-002 also were co-infected with HIV and the PaMZ regimen appeared to be effective independent of HIV status. See also http://www.aidsmap.com/Novel-TB-regimen-could-reduce-treatment-duration/page/2892700/

    18 March 2015 | Lancet (free registration required)
  • Tuberculosis and superbug strains 'ravaging' Europe, WHO warns

    As many as 1,000 people a day in Europe contract tuberculosis, and slow progress against the disease coupled with rising drug resistance mean the region is unlikely to defeat it until next century, health officials said on Tuesday.

    17 March 2015 | Reuters
  • UGA researchers discover potential treatment for drug-resistant tuberculosis

    The compound Nair and his colleagues developed works by binding to magnesium and specific amino acids found within the bacterium, interrupting the production of RNA. They were surprised to discover through preliminary experiments that it also exhibited strong anti-HIV properties, opening the door for dual therapeutic applications.

    20 February 2015 | University of Georgia press release
  • Addressing TB and drug-resistant TB in the Eastern Ukrainian region

    The challenges in addressing the implementation of comprehensive HIV, TB and viral hepatitis prevention and treatment activities in the Eastern Ukraine affected by the warfare is complicated and escalating every week.

    11 February 2015 | Stop TB Partnership
  • Access sought to tuberculosis drug from nutraceutical company

    Delamanid, only the second tuberculosis drug approved in 40 years by European regulators, uses a new mechanism of action to treat the disease by inhibiting the synthesis of a cell-wall component of Mycobacterium tuberculosis, the bacterium that causes tuberculosis. But patient advocates worry that the new drug may not reach the patients who need it because, according to these advocates, the developer of the drug has failed to aggressively study and market the medication in regions that need it most.

    05 February 2015 | Nature Medicine
  • Zimbabwe Faces Troubling Spike in Cases of Multi-Drug Resistant TB

    MDR-TB occurs when a strain of TB bacteria becomes resistant to two or more “first-line” antibiotic drugs prescribed to combat standard TB. According to the Ministry of Health and Child Welfare, cases of MDR-TB nearly doubled from 156 in 2011 to 244 cases in 2013. This was despite the fact that notifications for ordinary TB drastically declined from 47,000 in 2010 to 38,367 in 2012.

    26 January 2015 | Inter Press Service
  • Recent Ukranian Tuberculosis Outbreak Due to Lack of Medicine

    At a press conference convened by the AIDS Healthcare Foundation Ukraine today, a group of patients, experts and activists delivered a strong message that the country is experiencing a preventable tuberculosis (TB) outbreak this year due to the failure of state procurements to obtain essential medications. Activists urged that immediate measures be taken to address the crisis, including distributing needed medical supplies, creating transparent procurement systems and assessing the effectiveness of TB treatment for each patient in accordance to international standards.

    15 January 2015 | AIDS Healthcare Foundation press release
  • Johnson & Johnson announces collaboration between Janssen and USAID to expand access to anti-multidrug-resistant tuberculosis (MDR-TB) compound

    Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria.

    12 December 2014 | PR Newswire
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also